JAK2 and myeloproliferative disorder: For example, more than 90% of the non-leukemic classical myeloproliferative neoplasms (MPNs) are clearly driven by abnormal JAK2 activation, especially the cytokine receptor/JAK2 pathways and their downstream effectors (Passamonti et al., 2011).